Archive: Company News
Company News: Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L
— Study by international research team published in Nature Communications
— Preclinical proof-of-concept of CDR132L established
— Inhibition of a regulatory microRNA restores cardiac function
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in Nature Communications demonstrating that its lead compound CDR132L is able to reverse heart failure in preclinical in vivo studies. The research was conducted by an international team of scientists from Austria, Germany, Hungary, and the U.K.
Company News: Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe
— BGI Group responds to coronavirus crisis by providing reagent kits for molecular 2019-nCoV testing by next-generation sequencing and RT-PCR
— Ares Genetics to launch next-generation sequencing testing service for infection control and monitoring of 2019-nCoV evolution using BGI Group reagents
— Ares Genetics, Curetis Group and BGI Group to collaborate in the distribution of next-generations sequencing and PCR testing kits for 2019-nCoV
Ares Genetics GmbH, a Curetis Group company, and the Chinese genomics company BGI Group today announced that the companies will collaborate in making molecular testing for the new coronavirus 2019-nCoV available in Europe.
Company News: Curetis to Hold Extraordinary General Meeting on March 10, 2020
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today published the invitation to its Extraordinary General Meeting (EGM). The invitation follows the notice of effectiveness of the OpGen, Inc. S-4 filing received from the SEC on January 23, 2020.
Company News: Curetis To Attend Key Conferences in the First Half of 2020
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Curetis Group Companies will be attending several key conferences in the first half of 2020.